| INTRODUCTION
Therapeutic plasma exchange (TPE) or plasmapheresis is a technique wherein a patient's blood is processed to separate the cellular components from the plasma. 1 This separation occurs in an extracorporeal blood purification circuit and can be performed through hollow fiber plasma filters or with a centrifugal cell separator. 2 The primary purpose of this technique is to remove harmful components from the patient's plasma. Plasmapheresis has been performed in veterinary medicine since in the 1980s and remains relevant today for a variety of conditions such as immunologic diseases, [3] [4] [5] [6] [7] Ehrlichia canis infection, 8 kernicterus, 9 and multiple myeloma. 10 Recently, 3 case reports have described the use of TPE for ibuprofen, 11 meloxicam, 12 and carprofen 13 overdose.
The value of TPE for treating toxicities has been well established in the human medical literature. 14, 15 The utility of TPE varies depending on the characteristics of the particular toxin, and this technique is
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particularly suited to toxins with high levels of protein binding and a low volume of distribution (V d ). 15 Therapeutic plasma exchange carries some risks, and several complications have been reported in the human medical literature. 16, 17 The most common complications include patient discomfort and minor technical complications, although more serious issues such as hypotension, allergic reactions, bleeding, clot formation, and sepsis also have been reported. 16 Although similar complications likely also occur in veterinary patients, the largest published study so far consisted of 5 patients, 3 and thus an evaluation of complication frequency has not been performed.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used in both humans and animals as analgesics. These medications inhibit cyclooxygenase, which is involved in the production of prostanoids (including prostacyclin, prostaglandins, and thromboxanes). Numerous adverse effects of NSAID use and intoxication have been reported in veterinary medicine including vomiting, diarrhea, anorexia, melena, kidney injury, and central nervous system effects (seizures, ataxia, or coma). [18] [19] [20] Traditionally, treatment of NSAID toxicity has been limited to supportive and symptomatic treatment including aggressive decontamination, IV fluid administration, gastrointestinal (GI) protectant medications, antiemetics, and prostaglandin analogs, with the recent addition of IV lipid emulsion as a treatment option. 21 
| Medical records review
Details extracted from the medical record included signalment (age, sex, body weight, and breed), clinical and laboratory findings on presentation, details regarding treatment and clinicopathologic findings during hospitalization, and outcome. Details about presentation included the presence of any clinical signs before presentation, which NSAID was ingested, the estimated amount of NSAID ingested, the time since ingestion, and the initial laboratory findings (including serum biochemistry, urinalysis, and PCV). Records were reviewed for which adjunctive and supportive treatments the patients received during hospitalization, including the use of activated charcoal (ToxiBan;
Lloyd, Inc, Shenandoah, Iowa), induction of emesis, IV lipid infusion (Intralipid; Baxter Healthcare Corp, Deerfield, Illinois), IV fluids, and the use of any GI protective agents.
All patients underwent a single TPE treatment using a membrane filtration-based plasmapheresis unit (Prismaflex; Gambro Lundia AB, Lund, Sweden). Target plasma exchange volumes were calculated for each patient using a goal of either 1.0 or 1.5 patient plasma volumes exchanged. Each patient's plasma volume was calculated using the following equation: plasma volume = 0.08 × body weight
This equation is derived from the calculation of the patient's whole blood volume (80 mL/kg) multiplied by the percentage of that blood volume that consists of plasma. 24 The decision on each patient's goal was based on the total amount of NSAID ingested, with most patients having a goal of 1.5 plasma volumes exchanged because of the large amount of NSAID ingested. This value is taken from calculations involving the pharmacokinetics of solute removal that describe the amount of a substance expected to be removed based on the number of total plasma exchanges performed, which is 63% at 1 plasma exchange and 78% at 1.5 plasma exchanges. 25 The rate and duration 
| Statistical methods
Descriptive statistics were calculated. The Shapiro-Wilk test was done to evaluate data for normality. Bivariate statistics were performed to determine associations between various factors and categorical outcomes, including development of AKI, presence of GI signs, and occurrence of complications, with Fisher's exact test being used when the factor was categorical and a T-test being used when the data were continuous. Linear regression models were used to evaluate the effect of various factors on continuous outcomes (maximum serum creatinine concentration during hospitalization, change in serum creatinine concentration, and days of hospitalization). Statistical analysis was performed using commercial software (SAS Version 9.4; SAS Institute
Inc, Cary, North Carolina). In analyses, values of P < .05 were considered significant.
| RESULTS
Eleven dogs received TPE for NSAID overdose during the examined time period. The median age was 3 years (range, 2 months to 11 years).
Sex distribution was 7 (63.6%) neutered males, 2 (18.2%) spayed females, 1 (9.1%) intact male, and 1 (9.1%) intact female. 
| Overall outcome and probability of developing toxicity
Of the 11 cases, 3 (27.3%) dogs developed AKI, as defined by an increase in serum creatinine concentration of at least 0.3 mg/dL from baseline, and 6 (52.5%) developed GI signs. When development of AKI and GI signs were considered as categorical variables, none of the examined factors was predictive (see Table 1 ).
The maximum serum creatinine concentration during the course of hospitalization of these patients was 1.57 ± 1.07 mg/dL, with an average change in serum creatinine concentration from presentation to a maximum of 0.55 ± 1.02 mg/dL. Amount of NSAID ingested (per kilogram body weight) was associated with a higher maximum serum creatinine concentration (P = .04) and a larger change in serum creatinine concentration from baseline (P = .02). No other variable regarding elapsed time, examination or laboratory findings at presentation, or TPE parameters had a significant effect on the maximum serum creatinine concentration during hospitalization or change in serum creatinine concentration during hospitalization (see Table 2 ).
Dogs were hospitalized for a mean of 2.8 ± 1.8 days. The only variable with a significant effect on duration of hospitalization was PCV at presentation (P = .005).
All patients survived to discharge. Only 6 dogs (54.5%) had follow-up information after discharge from the hospital. so that the filter and lines could be replaced. One dog (9.1%) developed hypotension during the TPE session.
None of the investigated variables had a significant predictive effect on the likelihood of TPE complications in general or on the development of filter clotting. A higher serum sodium concentration was significantly (P = .04) associated with a higher risk of bleeding (see Table 3 ).
| Efficacy of other treatments during hospitalization
In addition to TPE, all dogs received other treatments during hospitalization. All 11 dogs received IV fluid therapy, IV lipid infusions, and pantoprazole (Protonix; Wyeth Pharmaceuticals Inc, Philadelphia, Pennsylvania). Lipid treatment was given according to standard protocol at our institution, which was an initial bolus of 1.5 mL/kg given over Complications from TPE were commonly observed with 54.5% of cases experiencing a complication, including evidence of clotting, hemorrhage, or hypotension. However, the occurrence of a complication did not have a significant effect on final outcome. A higher serum sodium concentration at presentation increased the risk of hemorrhage during or after TPE. Finally, none of the other treatments that these patients received had a significant impact on outcome.
Of note, all the patients in the study also were treated with IV lipid treatment, which is a standard acute intervention at our institution for patients presenting for NSAID toxicity. The use of IV lipid emulsion treatment has shown great promise in a case report of ibuprofen overdose 21 and in 3 cases of naproxen overdose. 22 Unfortunately, the effect that lipid treatment had on outcomes in our patients could not be fully evaluated because all patients received this treatment, and there was no control group that did not receive lipids. Lipid treatment also has the potential to alter the pharmacokinetics of NSAIDs, with the goal of causing more rapid elimination, which may affect the efficacy of TPE after its use. Regardless, it is impossible to infer from our study the different benefits of IV lipid treatment and TPE on patients with NSAID toxicity. Ideally, additional studies on the use of IV lipid treatment will clarify the results of these initial case reports 21, 22 and further elucidate the role this treatment has in patients with NSAID overdose.
Nonsteroidal anti-inflammatory drugs have long been recognized as a potential toxicity risk in both human and veterinary medicine. 18, 27, 28 Complications associated with NSAID ingestion include GI irritation or ulceration, AKI, central nervous system effects, ataxia, cardiac effects, and hepatotoxicity. 18, 21, 27 Toxicity has been reported both with overdoses as well as with standard therapeutic doses of NSAIDs. [18] [19] [20] In addition, although NSAIDs labeled for use in veterinary patients typically are obtained by prescription, multiple over-the-counter NSAIDs designed for use in humans are available. Our results suggest that the more common source of large NSAID overdoses in veterinary patients is over-the counter medications, because most of these patients presented for ingestion of ibuprofen or naproxen, with only 1 dog presenting for ingestion of an overdose of a veterinary prescription medication (deracoxib).
A previous study on ibuprofen overdose indicated that GI and renal consequences were common, with 55.5% and 55.6% of dogs developing these complications, respectively. 20 In our study, a similar number (54.5%) demonstrated GI signs, with fewer (27.3%) having evidence of AKI. This difference is likely because of the additional treatments our patients received, including TPE and IV lipid treatment. The frequency of GI signs in both studies is very similar, which may be related to the rapidity of development of GI complications compared to the delay in developing clinically recognizable kidney injury. 18 This hypothesis is Values are reported as mean ± SD. Plasma replacement (%) indicates the percentage of the total replacement fluid that was given as plasma. Abbreviations: ACT, activated clotting time; TPE, therapeutic plasma exchange.
supported by the observation that 5 dogs (45.5%) in our study presented having already developed signs of GI toxicity (primarily vomiting and regurgitation). In addition, the amounts of NSAID ingested were higher than those in a previous report in which only 27.6% of cases of ibuprofen ingestion were at a dosage higher than 200 mg/kg. 20 As a comparison, the lowest amount of ibuprofen ingested by dogs in our study was 283 mg/kg, with a range of 283-1480 mg/kg.
Although TPE is not a new technique in veterinary medicine, with multiple reports of its use in the 1980s, 3, 4, 7, 8, 29 there are few reports of its use for toxicity cases. In the past 2 years, 3 case reports of the use of TPE for NSAID overdose have been published for ingestions of meloxicam, 12 ibuprofen, 11 and carprofen. 13 Although all these were single case reports, the results were promising, with good clinical outcomes and evidence of an 82% reduction in plasma meloxicam concentrations, 12 an 85% reduction in plasma ibuprofen concentrations, 11 and a 51% decrease in plasma carprofen concentrations. 13 A limitation of our study is that plasma concentrations of the NSAIDs were not measured, and it is impossible to say how much of a decrease was achieved. The average number of plasma exchanges performed in our study was
1.08 ± 0.5, which should translate into an expected 67% decrease in plasma concentration of NSAID, although this is only an estimation.
The primary factor we identified that influenced outcome was the overall amount of NSAID ingested (per kilogram body weight). The role of dosage in NSAID toxicity previously has been investigated with different doses predicting the likelihood of developing GI signs or renal impairment. 18 In addition, the pharmacokinetics of certain NSAIDs is affected by the dose ingested, so that ingestion of a higher dose, as occurs in accidental overdose, can prolong the half-life of these medications and promote further toxic effects. 18 Of note, the dogs in our study likely do not represent the entire population of dogs presenting for NSAID ingestion. Therapeutic plasma exchange was only recommended for dogs with large amounts of NSAID ingestion that exceeded the amounts recognized to cause substantial renal impairment, and only such cases were considered in our study. It is probable that TPE is less necessary in animals presented for smaller amounts of NSAID ingestion, in which decontamination and supportive care may be sufficient.
We also identified that patients presented with lower PCV had significantly longer durations of hospitalization, although this did not change the overall outcome or likelihood of developing kidney disease.
The most likely explanation is that time of discharge from the hospital was determined largely by the progression of AKI, management of GI signs, or the resolution of any TPE complications. A low PCV could be interpreted as a sign of GI ulceration or as evidence of hemorrhage as a TPE complication, and thus it is likely that these patients were hospitalized for a longer course of treatment and monitoring before discharge.
An additional important finding of our study was the frequency of complications associated with TPE, with over half of patients developing some complication. In human medicine, the complication rate for TPE ranges from 25.6% to 36%. 16, 17 The most commonly observed complications in humans include fever, urticaria, or mild technical complications associated with blood flow. 16, 17 In reports of humans, complications associated with thrombosis or hemorrhage are rare and occur in fewer than 1.5% of cases. 16, 17 The cause of the increased frequency of complications in veterinary medicine compared to human medicine is likely multifactorial. One difficulty is that the average veterinary patient is much smaller, thus leading to slower blood flow through the circuit and a larger portion of the patient's blood being in the extracorporeal circuit at any time. An additional factor in this particular patient population is that NSAIDs have been shown to have various effects on coagulation parameters in dogs, 30 The last objective of our study was to identify if treatments other than TPE influenced the overall outcome. Because our study was retrospective, it was not possible to control the other treatments that these patients received. However, most patients received similar treatments consistent with the standards of care at our institution. All patients received IV fluids, IV lipid infusion, and pantoprazole. Most patients had similar decontamination protocols including induction of emesis (81.8%) and 1-5 doses of activated charcoal (81.8%). Most patients also received sucralfate (72.7%), with fewer receiving misoprostol (63.6%) and metronidazole (36.4%). These differences partially were based on clinician preference and partially a response to the clinical signs of individual patients. None of these treatments was shown to significantly change outcome in our patient population, but patient numbers were low because most patients received similar ancillary treatments. The effect of these treatments in conjunction with TPE would be better evaluated using a prospective study design with randomization to determine which treatments to provide. Because most patients in our study received these treatments, it is possible that their elimination would have adversely affected outcome.
The limitations of our study include relatively small case number as well as its retrospective design. Therapeutic plasma exchange is an advanced procedure requiring specialized equipment and training, and thus it is difficult to collect a large patient population to study its use.
These factors limit the overall analysis and conclusions that can be drawn from our study, and further studies using a larger population would be valuable as this technique becomes more common. In addition, the retrospective nature of our study meant that the treatments (both adjunctive treatments as well as the TPE protocols) could not be standardized. Similarly, diagnostic testing and monitoring were not standardized, leading to difficulties such as relatively few urinalysis results available from presentation as well as a lack of follow-up data in 45.5% of cases.
In conclusion, our study supports the use of TPE as an adjunctive treatment for dogs ingesting large amounts of NSAIDs. 
